‘One-of-a-kind’ new Alzheimer’s drug shows promise: ‘An exciting development’
“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the brains of people living with Alzheimer’s, preventing it from clumping together,” said Richard Oakley, associate director of research and innovation at the Alzheimer’s Society UK, which funded the research.